106 related articles for article (PubMed ID: 14647433)
1. Enhanced expression of MYCN leads to centrosome hyperamplification after DNA damage in neuroblastoma cells.
Sugihara E; Kanai M; Matsui A; Onodera M; Schwab M; Miwa M
Oncogene; 2004 Jan; 23(4):1005-9. PubMed ID: 14647433
[TBL] [Abstract][Full Text] [Related]
2. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
3. Suppression of centrosome amplification after DNA damage depends on p27 accumulation.
Sugihara E; Kanai M; Saito S; Nitta T; Toyoshima H; Nakayama K; Nakayama KI; Fukasawa K; Schwab M; Saya H; Miwa M
Cancer Res; 2006 Apr; 66(8):4020-9. PubMed ID: 16618721
[TBL] [Abstract][Full Text] [Related]
4. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
5. Cep63 recruits Cdk1 to the centrosome: implications for regulation of mitotic entry, centrosome amplification, and genome maintenance.
Löffler H; Fechter A; Matuszewska M; Saffrich R; Mistrik M; Marhold J; Hornung C; Westermann F; Bartek J; Krämer A
Cancer Res; 2011 Mar; 71(6):2129-39. PubMed ID: 21406398
[TBL] [Abstract][Full Text] [Related]
6. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
7. Centrosome amplification is correlated with ploidy divergence, but not with MYCN amplification, in neuroblastoma tumors.
Fukushi D; Watanabe N; Kasai F; Haruta M; Kikuchi A; Kikuta A; Kato K; Nakadate H; Tsunematsu Y; Kaneko Y
Cancer Genet Cytogenet; 2009 Jan; 188(1):32-41. PubMed ID: 19061778
[TBL] [Abstract][Full Text] [Related]
8. MYCN oncoprotein targets and their therapeutic potential.
Bell E; Chen L; Liu T; Marshall GM; Lunec J; Tweddle DA
Cancer Lett; 2010 Jul; 293(2):144-57. PubMed ID: 20153925
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
Alaminos M; Gerald WL; Cheung NK
Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
[TBL] [Abstract][Full Text] [Related]
10. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
[TBL] [Abstract][Full Text] [Related]
11. MYCN-mediated overexpression of mitotic spindle regulatory genes and loss of p53-p21 function jointly support the survival of tetraploid neuroblastoma cells.
Gogolin S; Batra R; Harder N; Ehemann V; Paffhausen T; Diessl N; Sagulenko V; Benner A; Gade S; Nolte I; Rohr K; König R; Westermann F
Cancer Lett; 2013 Apr; 331(1):35-45. PubMed ID: 23186832
[TBL] [Abstract][Full Text] [Related]
12. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma.
Alaminos M; Mora J; Cheung NK; Smith A; Qin J; Chen L; Gerald WL
Cancer Res; 2003 Aug; 63(15):4538-46. PubMed ID: 12907629
[TBL] [Abstract][Full Text] [Related]
14. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression.
Carroll PE; Okuda M; Horn HF; Biddinger P; Stambrook PJ; Gleich LL; Li YQ; Tarapore P; Fukasawa K
Oncogene; 1999 Mar; 18(11):1935-44. PubMed ID: 10208415
[TBL] [Abstract][Full Text] [Related]
15. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells.
Paffhausen T; Schwab M; Westermann F
Cancer Lett; 2007 May; 250(1):17-24. PubMed ID: 17141950
[TBL] [Abstract][Full Text] [Related]
16. Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncology.
Schwab M
Ann N Y Acad Sci; 2002 Jun; 963():63-73. PubMed ID: 12095930
[TBL] [Abstract][Full Text] [Related]
17. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections.
Tsai HY; Hsi BL; Hung IJ; Yang CP; Lin JN; Chen JC; Tsai SF; Huang SF
Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898
[TBL] [Abstract][Full Text] [Related]
18. Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma.
Gebauer S; Yu AL; Omura-Minamisawa M; Batova A; Diccianni MB
Genes Chromosomes Cancer; 2004 Dec; 41(4):297-308. PubMed ID: 15390183
[TBL] [Abstract][Full Text] [Related]
19. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
20. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients.
Combaret V; Audoynaud C; Iacono I; Favrot MC; Schell M; Bergeron C; Puisieux A
Cancer Res; 2002 Jul; 62(13):3646-8. PubMed ID: 12097268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]